Matthew Gline
Principal executive officer pay for Matthew Gline, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Roivant Sciences Ltd. (ROIV) FY2023–FY2026
Beat peersTSR 277% vs peer group 45% over FY2023–FY2026
Aligned: paid up as stock roseCAP $97,617,266→$382,436,735 while $100 invested went $149.00→$561.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $49.0M | $97.6M |
| FY2024 | $738,189 | $45.5M |
| FY2025 | $163.3M | $120.3M |
| FY2026 | $3.1M | $382.4M |
The company's "$100 invested" index ran $149.00 at FY2023 → $561.00 by FY2026 — an annualized return of 55.6%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 55.6%/yr at ROIV ( FY2023–FY2026). See the CEO track-record ranking for context.